Cost-effectiveness of SGLT2is Under the assumptions of our model, use of SGLT2is was cost-effective: SGLT2i use met the AU$28,000 per QALY willingness-to-pay threshold in most one-way sensitivity and scenario analyses in both populations, and also did so in most probabilistic sensitivity analyses, especially in the secondary prevention population
[DOI] [PubMed] [Google Scholar] 18.Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M, et al
Wegovy can sit at room temperature (59F86F) for up to 28 days before its first use
While such anecdotal evidence is not scientifically rigorous, it does provide real-world observations that can inform and guide more structured research
PlexusDx uses these insightsnot pharmacogenomicsto personalize your medication plan before side effects derail your treatment
Association of preconception paternal health on perinatal outcomes: analysis of U.S